Exploration of the barriers and enablers of benzodiazepines deprescribing in prisons: A qualitative study among health and social care professionals
Basic & Clinical Pharmacology & Toxicology · 2024
DOI: 10.1111/bcpt.13910 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2024. Verfasst von Clothilde Fay und 4 weiteren Autor:innen. Beteiligte Einrichtung: CHU Nantes, Pharmacy, Nantes University, France. Hauptthemen laut MEDLINE: Deprescriptions, General Practitioners. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The prison environment is a place of high consumption of benzodiazepines (BZDs) due to the anxiety and sleep disturbances, mental disorders, detoxification and trafficking.
Objective
The study aims to explore experiences of health and social care professionals on the use of BZDs in prisons, as well as the barriers and enablers to their deprescribing.
Method
Semistructured individual interviews with professionals working in a prison setting were performed between March and April 2022, based on an interview guide. They were recorded and transcribed using the NVivo software. A qualitative analysis using an inductive approach based on a thematic analysis was performed.
Results
Sixteen health professionals were interviewed, including psychiatrists, general practitioners, nurses, pharmacists, psychologists, musicologists and pharmacy technicians. The identified barriers to deprescribing BZDs were problems of coordination between prescribers, lack of time and alternatives. Concerning the enablers, therapeutic education groups, staff's awareness of the irrelevance of some medication and multi‐professional advice were identified.
Discussion
This study highlights the similarities in deprescribing difficulties between prison and other settings. Some of the levers identified in our study have shown their effectiveness in different settings.
Conclusion
Deprescribing is done most of the time in good conditions but requires an additional delay compared to the outside environment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CHU Nantes, Pharmacy, Nantes University, France.
- INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, Nantes, France.
- Inserm, ECEVE, Paris Cité University, Paris, France.
ORCID-Profile: Jean-François Huon
Zitieren
APA
Fay, C., Bonsergent, M., Saillard, J., Huon, J. F., & Prot-Labarthe, S. (2024). Exploration of the barriers and enablers of benzodiazepines deprescribing in prisons: A qualitative study among health and social care professionals. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13910
Vancouver
Fay C, Bonsergent M, Saillard J, Huon JF, Prot-Labarthe S. Exploration of the barriers and enablers of benzodiazepines deprescribing in prisons: A qualitative study among health and social care professionals. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.13910
BibTeX
@article{Fay2024,
author = {Fay, Clothilde and Bonsergent, Marion and Saillard, Justine and Huon, Jean-François and Prot-Labarthe, Sonia},
title = {Exploration of the barriers and enablers of benzodiazepines deprescribing in prisons: A qualitative study among health and social care professionals},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2024},
doi = {10.1111/bcpt.13910}
}
EUVIMED